ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Open Access
Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)Recommended Conferences
- 8th Asian Biosimilars Congress
August 10-12, 2017 Beijing, China - 4th International Conference on Clinical Trials
September 11-13, 2017 San Antonio, Texas, USA - World Congress on Biotherapeutics and Bioanalytical Techniques
September 11-13, 2017, Dallas, Texas, USA - 2nd International Conference and Expo on Generic Drug Market and Contract Manufacturing
September 25-26, 2017 Frankfurt, Germany - 3rd International Conference and Expo on Drug Discovery & Designing
September 25-27, 2017 Vienna ,Austria - European Biopharma Congress
November 16-17, 2017 Vienna, Austria
Recommended Journals
Relevant Topics
- Advances in Bioavailability
- Advances in pharmaceutical analytical methods
- Air analysis
- Anthropology Biomedicine
- Antigen â Antibody Reaction
- Anvisa Bioequivalence
- Anvisa regulatory guidelines
- Applied Biomedicine
- BA/BE Studies
- Bioanalysis Methods
- Bioanalytical Chemistry
- Bioanalytical Method Validation
- Bioequivalence Anticancers
- Bioequivalence Antidiabetics
- Bioequivalence Antidiuretics
- Bioequivalence Antipsychotics
- Bioequivalence Cardiovascular Products
- Bioequivalence Study Design
- Bioequivalence Study Protocols
- Biomedicine and Pharmacotherapy
- Biopharmaceutics
- Biosimilars
- British regulatory guidelines
- Chemical analysis
- Chromatographic Techniques
- Clinical Cancer Trials
- Clinical Drug Trial
- Competitive analysis of drugs
- Computational Biomedicine
- Drug Delivery using Nanotechnology
- Drug Designing
- Drug analysis
- Drug devices
- European Bioequivalence
- Europian regulatory guidelines
- Experimental Drug Trial
- FDA Bioequivalence
- Fragment Based Drug Design
- Heat Shock Proteins
- In Silico Methods
- In vitro Bioequivalence
- Japan regulatory guidelines
- Marine Biomedicine
- Mass Spectroscopy
- Medical Biology
- Medical devices regulations
- Molecular Biomedicine
- Molecular Epidemiology
- Molecular Modeling
- NMR Applications in Biomedicine
- Nanomedicals
- Negative Results in Biomedicine
- Paid Clinical Trials
- Peptidomimetic
- Pharmaceutical analysis
- Pharmaceutical analytical market
- Pharmaceutical care
- Pharmaceutical companies and regulatory guidelines
- Pharmaceutical ethics
- Pharmaceutical formulation
- Pharmaceutical technology
- Pharmaceutics
- Product analysis and marketing
- Protease Substrate/Inhibitor
- Quality assurance in pharmaceutical analysis
- Quality assurance in regulatory affairs
- Receptor Agonist/ Antagonist
- Regulatory Requirements in Bioequivalence
- Regulatory affairs
- Regulatory affairs for clinical trails
- Regulatory compliance
- Regulatory consulting and market analysis
- Regulatory requirements of pharmaceutical products
- Regulatory services and market analysis
- Spectrometry
- Sports Biomedicine
- Structure Based Drug Design
- Systems Biomedicine
- US FDA guidelines
- Validation
- screening and Drug Design
Kun Fang Ma |
||
| School of Pharmacy at Nanjing Medical University, China. | ||
| Biography | ||
Dr.Kun Fang Ma GR is currently working in School of Pharmacy at Nanjing Medical University, China. |
||
| Research Interest | ||
Pharmacokinetics, Bioequivalence & Bioavailability. |
||
| Publications | ||
|
Mei Juan Ding, Li Hua Yuan, Yun Li, Shu Wang, Xiao Li Wu, Jie Liu, Kun Fang Ma, Hong Wei Fan, Zhen Yu Lu, Hui Juan Xu and Xue Min Zhou Research Article: JBB/Vol.3.2 032-037 (2011) |
||
Global Speakers in the subjectGlobal Experts in the subject |
||
Relevant Conferences
- Intellectual Property Rights
Asian Biosimilars (China) - BCS & IVIVC Based Biowaivers
Asian Biosimilars (China) - Bioequivalence Assessment
Asian Biosimilars (China) - Biosimilar Market Analysis
Asian Biosimilars (China) - Biosimilars Analytical Strategies
Asian Biosimilars (China) - Biosimilars Innovator Pharmaceutical Products
Asian Biosimilars (China) - Biosimilars Market- Challenges & Prospects
Asian Biosimilars (China) - Biosimilars Research Pipeline
Asian Biosimilars (China) - Biosimilars- Hatch-Waxman Act & BPCI Act
Asian Biosimilars (China) - Challenges in Developing Biosimilars
Asian Biosimilars (China) - Clinical Studies on Biosimilars
Asian Biosimilars (China) - Cost Analysis of Biosimilars
Asian Biosimilars (China) - Current Developments in The Field of Biosimilars
Asian Biosimilars (China) - Emerging Biosimilars in Therapeutics
Asian Biosimilars (China) - Emerging Trends in Biosimilars
Asian Biosimilars (China) - Entrepreneurs Investment Meet
Asian Biosimilars (China) - Globalization of Biosimilars
Asian Biosimilars (China) - Latest Biosimilars in Asian Scenario
Asian Biosimilars (China) - Legal Issues
Asian Biosimilars (China) - Pharmacovigilance of Biosimilars
Asian Biosimilars (China) - Regulatory Approach For Biosimilars
Asian Biosimilars (China) - Biomarkers in Drug Discovery & Development
Drug Discovery 2017 (Austria) - Novel Therapeutic approaches in treating Ocular Diseases
Drug Discovery 2017 (Austria) - Advanced Trends in Medicinal Chemistry in drug discovery and designing
Drug Discovery 2017 (Austria) - Antibody Research
Drug Discovery 2017 (Austria) - Computational chemistry
Drug Discovery 2017 (Austria) - Computer Aided Drug Design (CADD)
Drug Discovery 2017 (Austria) - Drug Designing
Drug Discovery 2017 (Austria) - Immunotherapy
Drug Discovery 2017 (Austria) - Innovative Drug Discovery and Nanotechnology
Drug Discovery 2017 (Austria) - Insilco Drug Discovery
Drug Discovery 2017 (Austria) - Integrated Strategies for Drug Discovery
Drug Discovery 2017 (Austria) - Novel Detection Technologies and Drug Discovery
Drug Discovery 2017 (Austria) - Perspective In Drug Discovery
Drug Discovery 2017 (Austria) - Pharmaceutical Research & Development
Drug Discovery 2017 (Austria) - Proteomics Drug Discovery
Drug Discovery 2017 (Austria) - Recent Advances in Spectroscopy
Drug Discovery 2017 (Austria) - Array of Clinical Trials in Biosimilars
Generics-Biosimilars 2017 (Italy) - Biologics & Biosimilars
Generics-Biosimilars 2017 (Italy) - Biosimilar development challenges
Generics-Biosimilars 2017 (Italy) - Biosimilars Differentiated Through Novel Drug Delivery Technologies
Generics-Biosimilars 2017 (Italy) - Biosimilars Uptake & Patient Safety
Generics-Biosimilars 2017 (Italy) - Case Study Mitigating Risk in Biosimilar Development
Generics-Biosimilars 2017 (Italy) - Chronicles of a Biosimilar Production Facility
Generics-Biosimilars 2017 (Italy) - Developing Biosimilars And Biobetters
Generics-Biosimilars 2017 (Italy) - Entrepreneurs Investment Meet
Generics-Biosimilars 2017 (Italy) - Generic Drugs, Generic Pills and Generic Medication
Generics-Biosimilars 2017 (Italy) - Generics& Biosimilars Industry Strategy
Generics-Biosimilars 2017 (Italy) - Global Generic Trends & Global Pharma Market
Generics-Biosimilars 2017 (Italy) - GMP, GCP and Quality Control
Generics-Biosimilars 2017 (Italy) - Innovation & Technology for Biosimilar Development
Generics-Biosimilars 2017 (Italy) - Integrated Supply Chain Management and Logistics
Generics-Biosimilars 2017 (Italy) - Licensing, Manufacturing& Health Economics
Generics-Biosimilars 2017 (Italy) - Office of Generic Drugs (OGD)
Generics-Biosimilars 2017 (Italy) - Office of Generic Drugs (OGD)
Generics-Biosimilars 2017 (Italy) - Patent Access& Intellectual property& FDA Regulations
Generics-Biosimilars 2017 (Italy) - Pharma Pricing & Market Access
Generics-Biosimilars 2017 (Italy) - Pharmacology and Drug Developement
Generics-Biosimilars 2017 (Italy) - Pharmacovigilance & Safety of Biosimilars
Generics-Biosimilars 2017 (Italy) - Protein Biotherapeutics & biosimilars
Generics-Biosimilars 2017 (Italy) - Quality Control/ R & D
Generics-Biosimilars 2017 (Italy) - Drug Metabolism
Euro Biopharma 2017 (Austria) - Bioavailability/Bioequivalence on Biopharmaceutical Products
Euro Biopharma 2017 (Austria) - Biologics and Biosimilars
Euro Biopharma 2017 (Austria) - Biopharmaceutical Companies & Market Analysis
Euro Biopharma 2017 (Austria) - Biopharmaceutical Pharmacovigilance
Euro Biopharma 2017 (Austria) - Biopharmaceutics: Drug Discovery and Development
Euro Biopharma 2017 (Austria) - Biotechnological Products
Euro Biopharma 2017 (Austria) - Cellular and Gene Therapy
Euro Biopharma 2017 (Austria) - Clinical Trials on Biopharmaceutical Products
Euro Biopharma 2017 (Austria) - Drug Delivery System of Biopharmaceutical Products
Euro Biopharma 2017 (Austria) - Drug Disposition & Pharmacokinetics
Euro Biopharma 2017 (Austria) - Drug Dissolution of Biopharmaceutical Products
Euro Biopharma 2017 (Austria) - Entrepreneurs Investment Meet
Euro Biopharma 2017 (Austria) - Gene Therapy
Euro Biopharma 2017 (Austria) - Oral Drug Absorption
Euro Biopharma 2017 (Austria) - Pharmaceutical Regulatory Affairs And IPR
Euro Biopharma 2017 (Austria) - Pharmacodynamics
Euro Biopharma 2017 (Austria) - Therapeutic Biological Products
Euro Biopharma 2017 (Austria) - Bioethics and Quality Regulation
Clinical Trials 2017 (USA) - Clinical and Medical Case Reports
Clinical Trials 2017 (USA) - Clinical Data Management and Statistics
Clinical Trials 2017 (USA) - Clinical Research & Clinical Trials
Clinical Trials 2017 (USA) - Clinical Study Designs
Clinical Trials 2017 (USA) - Clinical Trial Site Management and Business Development
Clinical Trials 2017 (USA) - Clinical Trials on different Diseases
Clinical Trials 2017 (USA) - Conducts of Clinical Trials
Clinical Trials 2017 (USA) - CRO/Sponsorship Clinical Trials
Clinical Trials 2017 (USA) - Drug Discovery and Development
Clinical Trials 2017 (USA) - Entrepreneurs Investment Meet
Clinical Trials 2017 (USA) - Future of Clinical Trials
Clinical Trials 2017 (USA) - Globalization of Clinical Trials
Clinical Trials 2017 (USA) - Innovations in Clinical Trials
Clinical Trials 2017 (USA) - Outsourcing in Clinical Trials
Clinical Trials 2017 (USA) - Patient-Centric Clinical Trials
Clinical Trials 2017 (USA) - Pharmacovigilance and Drug Safety
Clinical Trials 2017 (USA) - Post-marketing Surveillance
Clinical Trials 2017 (USA) - Research and Trials on AIDS / Cancer / Diabetes
Clinical Trials 2017 (USA) - Advancement in Biotherapeutics
Biotherapeutics 2017 (USA) - Advancements in Biotherapeutics
Biotherapeutics 2017 (USA) - Analytical Biotherapeutics
Biotherapeutics 2017 (USA) - Analytical Biotherapeutics
Biotherapeutics 2017 (USA) - Immunopharmacotherapy
Biotherapeutics 2017 (USA) - Innovative Therapies for Serious Diseases
Biotherapeutics 2017 (USA) - Bioanalytical Techniques
Biotherapeutics 2017 (USA) - Bioanalytical techniques
Biotherapeutics 2017 (USA) - Biotherapy
Biotherapeutics 2017 (USA) - Biotherapy
Biotherapeutics 2017 (USA) - Cancer Biotherapeutics
Biotherapeutics 2017 (USA) - Cancer Biotherapeutics
Biotherapeutics 2017 (USA) - Chromatographic methods
Biotherapeutics 2017 (USA) - Chromatographic Techniques
Biotherapeutics 2017 (USA) - Clinical Biotherapeutics
Biotherapeutics 2017 (USA) - Clinical Biotherapeutics
Biotherapeutics 2017 (USA) - Cystine-Knot Micro-Proteins
Biotherapeutics 2017 (USA) - Drug Analysis
Biotherapeutics 2017 (USA) - Drug Metabolism Studies
Biotherapeutics 2017 (USA) - Instrumental analytical chemistry
Biotherapeutics 2017 (USA) - MicroRNAs (miRNAs) Biotherapeutics
Biotherapeutics 2017 (USA) - Oncolytic Virotherapy
Biotherapeutics 2017 (USA) - Peptide Therapeutics
Biotherapeutics 2017 (USA) - Stem Cell Therapy
Biotherapeutics 2017 (USA) - Stem Cell Therapy
Biotherapeutics 2017 (USA) - Structural Analysis of Small Organic Molecules
Biotherapeutics 2017 (USA) - Synthetic Immunology
Biotherapeutics 2017 (USA)
